(Q38071132)

28 August 2017

0 references

1 reference

title

Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis (English)

1 reference

28 August 2017

Tomohiro Funakoshi

1

1 reference

28 August 2017

Yuichi J Shimada

series ordinal

2

1 reference

28 August 2017

publication date

3 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

52

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

691-702

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Effect of sunitinib on growth and function of FRTL-5 thyroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Sunitinib induces hypothyroidism with a markedly reduced vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

How does sunitinib cause hypothyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Unanswered questions regarding the management of sunitinib-induced hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

Subclinical thyroid disease: scientific review and guidelines for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.752579

10.3109/0284186X.2012.752579

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference